Greenwich Wealth Management LLC purchased a new position in shares of Intrexon Corp (NYSE:XON) in the fourth quarter, HoldingsChannel reports. The fund purchased 50,000 shares of the biotechnology company’s stock, valued at approximately $576,000.

A number of other large investors have also recently added to or reduced their stakes in the business. Alliancebernstein L.P. boosted its position in Intrexon by 0.6% during the 2nd quarter. Alliancebernstein L.P. now owns 32,610 shares of the biotechnology company’s stock worth $786,000 after acquiring an additional 200 shares during the last quarter. Raymond James Financial Services Advisors Inc. boosted its position in Intrexon by 4.4% during the 2nd quarter. Raymond James Financial Services Advisors Inc. now owns 59,146 shares of the biotechnology company’s stock worth $1,425,000 after acquiring an additional 2,468 shares during the last quarter. Bank of New York Mellon Corp boosted its position in Intrexon by 1.4% during the 3rd quarter. Bank of New York Mellon Corp now owns 237,373 shares of the biotechnology company’s stock worth $4,512,000 after acquiring an additional 3,234 shares during the last quarter. Advisor Group Inc. boosted its position in Intrexon by 61.5% during the 2nd quarter. Advisor Group Inc. now owns 8,797 shares of the biotechnology company’s stock worth $212,000 after acquiring an additional 3,351 shares during the last quarter. Finally, Teachers Advisors LLC boosted its position in Intrexon by 7.9% during the 2nd quarter. Teachers Advisors LLC now owns 57,840 shares of the biotechnology company’s stock worth $1,393,000 after acquiring an additional 4,234 shares during the last quarter. 75.10% of the stock is owned by hedge funds and other institutional investors.

In related news, CEO Randal J. Kirk acquired 1,000,000 shares of the company’s stock in a transaction dated Friday, January 19th. The shares were bought at an average price of $12.50 per share, for a total transaction of $12,500,000.00. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Corporate insiders own 56.30% of the company’s stock.

A number of research firms have weighed in on XON. ValuEngine downgraded Intrexon from a “sell” rating to a “strong sell” rating in a research report on Friday, February 2nd. Zacks Investment Research raised Intrexon from a “sell” rating to a “hold” rating in a research report on Monday, January 22nd. Bank of America dropped their price objective on Intrexon from $25.00 to $21.00 and set a “neutral” rating on the stock in a research note on Friday, November 10th. Stifel Nicolaus upped their price objective on Intrexon from $39.00 to $57.00 and gave the stock a “buy” rating in a research note on Friday, November 10th. Finally, Northland Securities reiterated a “buy” rating and set a $21.00 price objective on shares of Intrexon in a research note on Friday, November 10th. Two equities research analysts have rated the stock with a sell rating, two have assigned a hold rating and five have issued a buy rating to the stock. The company currently has a consensus rating of “Hold” and a consensus target price of $38.50.

Shares of Intrexon Corp (NYSE XON) opened at $12.65 on Tuesday. Intrexon Corp has a 12 month low of $10.26 and a 12 month high of $26.99. The company has a current ratio of 2.05, a quick ratio of 1.85 and a debt-to-equity ratio of 0.01.

ILLEGAL ACTIVITY WARNING: This piece of content was originally published by TheOlympiaReport and is the sole property of of TheOlympiaReport. If you are reading this piece of content on another website, it was stolen and republished in violation of United States and international copyright and trademark law. The legal version of this piece of content can be accessed at https://theolympiareport.com/2018/02/13/50000-shares-in-intrexon-corp-xon-purchased-by-greenwich-wealth-management-llc.html.

Intrexon Company Profile

Intrexon Corporation (Intrexon) forms collaborations to create biologically-based products and processes using synthetic biology. The Company’s domestic operations are in California, Florida, Maryland, and Virginia, and its primary international operations are in Belgium and Hungary. The Company designs, builds and regulates gene programs, which are deoxyribonucleic acid (DNA) sequences that consist of genetic components.

Want to see what other hedge funds are holding XON? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Intrexon Corp (NYSE:XON).

Institutional Ownership by Quarter for Intrexon (NYSE:XON)

Receive News & Ratings for Intrexon Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intrexon and related companies with MarketBeat.com's FREE daily email newsletter.